A small trial using 17 patients tested the combination of sorafenib and MEK inhibitor trametinib in treatment-naïve HCC patients, which demonstrated safety and tolerability of the combination, but did not show a significant anti-cancer effect [40]. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.